Provided by Tiger Trade Technology Pte. Ltd.

Natera

199.99
+13.157.04%
Post-market: 199.990.00000.00%19:58 EDT
Volume:1.42M
Turnover:280.72M
Market Cap:28.34B
PE:-131.35
High:200.56
Open:190.34
Low:190.29
Close:186.84
52wk High:256.36
52wk Low:125.38
Shares:141.73M
Float Shares:135.00M
Volume Ratio:1.71
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5225
EPS(LYR):-1.5269
ROE:-14.32%
ROA:-9.54%
PB:16.55
PE(LYR):-130.98

Loading ...

Natera price target raised to $260 from $250 at Evercore ISI

TIPRANKS
·
Feb 27

Natera Is Maintained at Outperform by Baird

Dow Jones
·
Feb 27

Piper Sandler Keeps Their Buy Rating on Natera (NTRA)

TIPRANKS
·
Feb 27

Guggenheim Reaffirms Their Buy Rating on Natera (NTRA)

TIPRANKS
·
Feb 27

Natera price target raised to $280 from $270 at Barclays

TIPRANKS
·
Feb 27

Is It Time To Reassess Natera (NTRA) After Strong Multi Year Share Price Gains

Simply Wall St.
·
Feb 27

Natera: Underpenetrated Growth, Emerging Catalysts, and a Clear Path to Cash Flow Support a Buy Rating

TIPRANKS
·
Feb 27

Natera Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 27

Natera reports FY25 EPS ($1.52), consensus ($2.42)

TIPRANKS
·
Feb 27

Natera Q4 Sales $665.500M Beat $592.417M Estimate

Benzinga
·
Feb 27

GUIDANCE: (NTRA) Natera Expects 2026 Revenue Range $2.62B - $2.70B, vs. FactSet Est. of $2.61B

MT Newswires Live
·
Feb 27

Natera Q4 total revenue rises 39.8% to USD 665.5 million

Reuters
·
Feb 27

BRIEF-Natera Q4 Operating Expenses USD 466.5 Million

Reuters
·
Feb 27

Natera Inc - Anticipates $2.62-$2.70 Bln Revenue in 2026

THOMSON REUTERS
·
Feb 27

Natera Inc Q4 REV $665.5 Mln

THOMSON REUTERS
·
Feb 27

Natera says Phase 2 SINERGY trial met primary endpoint

TIPRANKS
·
Feb 24

BRIEF-Successful Readout Of Prospective Phase 2 Sinergy Trial Supports Signateratm Mrd-Guided Treatment

Reuters
·
Feb 24

Natera Reports Phase 2 SINERGY Trial Success for Signatera-Guided Treatment in Head and Neck Cancer

Reuters
·
Feb 24

Natera Inc - Trial Achieves 63% Response Rate, Reduces Chemotherapy in 74% of Patients

THOMSON REUTERS
·
Feb 24

Successful Readout of Prospective Phase 2 Sinergy Trial Supports Signateratm Mrd-Guided Treatment in Head and Neck Cancer

THOMSON REUTERS
·
Feb 24